This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Effectiveness results
Before implementation of the protocol, filgrastim was discontinued in 29% of patients when the ANC was 1000 cells/cubic millimetre and in 48% of patients when the ANC was greater than 1000 cells/cubic millimetre.
After implementation of the protocol, filgrastim was discontinued in 76% of patients when the ANC was greater than 1500 cells/cubic millimetre for two days after the nadir, 12% of patients did not have therapy discontinued at that point.
67% of patients were febrile before the protocol was implemented and 56% were febrile afterward.
10% of patients had documented infections before implementation, compared with 12% afterward.
The average ANC at which filgrastim was discontinued before and after the protocol was implemented was 6,839 and 5,538 cells/cubic millimetre, respectively.
The mean daily dose was 412 microgram before implementation and 375 microgram after implementation.
The mean duration of therapy was 4 days before implementation and 4.8 days after implementation.
Filgrastim was discontinued by a pharmacist in 32% of cases.
There was no significant difference in the rate of infections before and after implementation of the protocol (10% versus 12%, p>0.05).
There was no increase in episodes of febrile neutropenia. There were no cases of sepsis.
Clinical conclusions
A pharmacy-based protocol for discontinuing filgrastim therapy in oncology patients did not delay subsequent chemotherapy cycles or increase the infection rate.
Measure of benefits used in the economic analysis
Given that clinical effectiveness results were equal across groups, the authors conducted a cost-minimisation analysis.
Direct costs
Direct costs were not discounted due to the short time horizon of the study (less than one year). Quantities and costs were not reported separately. Direct costs related to drug costs. The quantity/cost boundary adopted was that of the health service. The estimation of quantities and costs was based on actual data. Costs and quantities were collected from the community hospital and costs of pharmaceuticals. The price year was not reported.
Synthesis of costs and benefits
Cost and benefits were not combined. The results showed that a pharmacy-based protocol for discontinuing filgrastim therapy in oncology patients saved the study institution more than $22,000 in the first six months without delaying subsequent chemotherapy cycles or significantly increasing the infection rate. This suggests that the intervention is a weakly dominant strategy.
Authors' conclusions
A pharmacy-based protocol for discontinuing filgrastim therapy in oncology patients saved a community hospital more than $22,000 in the first six months with no adverse impact on the drug's effectiveness.
CRD COMMENTARY -Selection of comparators
A justification was given for the comparator used, namely no filgrastim protocol. You, as a user of the database, should decide if this health technology is relevant to your setting.
Validity of estimate of measure of effectiveness
The analysis was based on a before-and-after study, which was appropriate for the study question. The study sample was representative of the study population and patient groups were shown to be comparable at analysis. The analysis of effectiveness was handled credibly. However, in terms of limitations it is necessary to note that the authors' choice of selecting only every fourth patient in each period, in conjunction with the before and after design, will limit the validity of the results due to potential bias and confounding variables. Analyses of new guidelines are often assessed using these methods but their limitations could be addressed using randomisation techniques and concurrent controls, thus improving the validity of the results.
Validity of estimate of measure of benefit
The analysis of benefits was based on the therapeutic equivalence of treatment alternatives. The economic analysis therefore included only costs. The authors did not consider improved quality of life resulting from fewer injections and, perhaps, more comprehensive patient monitoring.
